Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015 and headquartered in Buenos Aires, Argentina, GRIDX is a pioneering venture studio dedicated to the bioeconomy. With a fund size of $30 million, GRIDX aims to leverage the rich bioscience knowledge and talent present in Latin America to create innovative startups that have a global impact. The firm operates as a venture studio, which distinguishes it from traditional venture capital firms by actively participating in the development of its portfolio companies. GRIDX employs nearly 700 people, with a significant majority based in Latin America, and has built a reputation as a leading platform in the region's bioeconomy sector.
GRIDX's mission is to harness the convergence of biology, digital tools, and advanced engineering to foster startups that contribute to both human and planetary health. The firm has successfully raised and managed multiple funds, with its second fund closing in mid-2025. GRIDX's leadership includes notable figures such as Marcos Galperin, founder of MercadoLibre, and Hugo Sigman, a prominent pharmaceutical entrepreneur. This backing from top executives in Argentina enhances GRIDX's credibility and operational capacity, positioning it as a key player in the Latin American startup ecosystem.
GRIDX focuses on investing in sectors that are integral to the bioeconomy, including healthcare, agriculture, bioindustry, and materials. The firm emphasizes life-compatible production systems that promote sustainability and health. Their investment strategy is particularly geared towards startups innovating in agri-food, bioindustry, human health, and deep biotech. GRIDX primarily targets seed and Series A stages, with check sizes ranging from $200,000 to $1.5 million, allowing them to support early-stage companies as they develop their products and market strategies.
With a strong emphasis on the Latin American region, GRIDX seeks to identify and back founders who are passionate about transforming scientific research into viable business models. The firm looks for innovative solutions that address pressing challenges in the bioscience sector, leveraging the unique biodiversity and scientific talent available in Latin America. By focusing on these sectors, GRIDX aims to build companies that not only achieve commercial success but also contribute positively to society and the environment.
GRIDX boasts a diverse portfolio of 81 companies, showcasing its commitment to advancing the bioeconomy in Latin America. Notable investments include:
This portfolio reflects GRIDX's strategic focus on sectors that align with its mission of promoting human and planetary health through innovative biotechnology solutions.
Marcos Galperin: Founder of MercadoLibre and a key backer of GRIDX, bringing extensive experience in e-commerce and technology.
Hugo Sigman: A prominent pharmaceutical entrepreneur and investor, contributing valuable insights into the healthcare sector.
To pitch GRIDX, founders should visit their website at gridexponential.com. They prefer detailed pitches that clearly outline the business model, market opportunity, and alignment with their investment focus on the bioeconomy. Warm introductions are beneficial, but cold applications are also accepted.
GRIDX operates a venture studio program that focuses on transforming scientific research into startups. This program provides resources, mentorship, and operational support to help entrepreneurs navigate the complexities of the biotech landscape. Founders interested in participating can apply through GRIDX's website.
Recently, GRIDX has expanded its portfolio to include 81 biotech startups, reflecting its commitment to advancing the bioeconomy in Latin America. The firm closed its second fund of $30 million in mid-2025, positioning itself for further growth and investment in innovative bioscience solutions.
GRIDX primarily invests in seed and Series A stages, providing early-stage companies with the necessary capital to develop their products and market strategies.
Founders can pitch GRIDX through their website at gridexponential.com. It is advisable to prepare a comprehensive pitch that outlines the business model, market opportunity, and how the startup aligns with GRIDX's focus on the bioeconomy.
GRIDX focuses on sectors related to healthcare, agriculture, bioindustry, and materials, with a strong emphasis on life-compatible production systems that promote sustainability and health.
GRIDX typically invests between $200,000 and $1.5 million in its portfolio companies, allowing for both initial investments and follow-on funding as companies grow.
GRIDX primarily invests in Latin America, targeting countries such as Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Uruguay.
The application process involves submitting a pitch through their website. Founders should ensure their proposals align with GRIDX's investment focus on the bioeconomy.
GRIDX offers hands-on support to its portfolio companies, helping them navigate the complexities of the biotech landscape and transform scientific research into viable startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.